Full-Time
Machine Operator 1
1st Shift
Medline
10,001+ employees
Manufacturer and distributor of medical supplies
Compensation Overview
$17.25 - $25/hr
Mankato, MN, USA
In Person
 Operations & Logistics (1) |
|---|
Get referred to Medline
See people who can refer or advise you
- Previous production or manufacturing experience is required.
- The ability to read and communicate in English is required.
- Basic addition and subtraction skills are required.
- The ability to stand and/or walk for long periods, up to 8 hours per day, is required.
- Repetitive hand movements are required to place components in trays and wrap the tray.
- The ability to lift totes of components and objects weighing up to 50 pounds is required.
- The ability to follow clean-room procedures, including attire and personal hygiene requirements, is required.
- Operate, monitor, and set up production and packaging equipment safely.
- Perform minor maintenance and repairs, address equipment issues, and involve maintenance when necessary.
- Verify the correct inserts, labels, and pouches for each lot.
- Check product output for quality and accuracy and adjust processes to maintain quality.
- Document machine attributes and parameters on required forms and logs.
- Weigh products before packaging and operate equipment to process and package materials.
- Load and transport finished products, seal packaging, and verify packaging integrity.
- Communicate with packers about line status and new jobs.
- Complete requisition forms for shortages and scrap components and complete scrap reports.
- Assist in maintaining proper line clearance and perform backup duties and other assigned projects.
- Maintain a clean and safe work area and ensure orderly housekeeping.
- Clean equipment and production areas regularly.
- A high school diploma or equivalent is preferred.
Medline Industries designs, produces, and distributes medical supplies for healthcare settings. It combines manufacturing and distribution to control product quality and sell directly to hospitals and other healthcare providers, offering a wide range of Medline-branded and third-party products. Its products include gowns, uniforms, gloves, and other medical consumables, produced and then delivered through a direct-to-provider model. The company differentiates itself with vertical integration that bypasses traditional distributors, a long-standing family-led culture that continued after a 2021 private-equity-led majority investment, and the scale to serve healthcare systems with a broad catalog. The goal is to supply healthcare providers with a comprehensive, high-quality catalog of medical products while expanding market reach and maintaining reliability through direct manufacturing-and-distribution control.
Company Size
10,001+
Company Stage
IPO
Headquarters
Northfield, Illinois
Founded
1966
Get referred to Medline
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026 Q2 sales rose 11.6% to $7.7 billion.
- First-half 2026 organic sales guidance increased to 9%–10%, driven by new signings.
- Perris and Tracy replacements add 1.6 million square feet, restoring California capacity.
What critics are saying
- FDA warning letters on April 8 and June 2, 2026 expose manufacturing controls failures.
- Tracy fire caused $336 million losses and lowers 2027 earnings through remediation and automation.
- Securities investigations from Kaplan Fox and KTMC target MDLN after disclosures and stock drops.
What makes Medline unique
- Medline's vertical integration spans manufacturing, distribution, and supply-chain software across care settings.
- July 2026 Allina deal expands prime-vendor reach across 12 hospitals and 90 clinics.
- California footprint rebuilds faster than competitors, preserving regional service continuity after the Tracy fire.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Medline tallies tariff refunds as Q2 sales rise 11.6%. Brian Warmoth | Aug 18, 2026 2.5 minutes Medical supplies distributor Medline recorded $243 million in tariff refunds during its fiscal year through Q2, helping drive revenue growth even as a California warehouse fire weighed on quarterly profits. Medline Inc. recorded $243 million in net tariff refunds that it realized during its current fiscal year by the end of its Q2. Those funds arrived against the backdrop of an overall net income decline of 58.3% year over year to $139 million for the quarter ended June 27. Despite that decrease, the medical supply company outlined its growth plans for the rest of its fiscal year. In addition, it reported an overall sales increase of 11.6% to $7.7 billion for the same period. Jim Boyle, chief executive officer of Medline, said Q2 reflected "strong execution of our growth strategy" and "operational resilience." What drove Medline sales in Q2? Medline credited existing customer growth and new customer signings from 2025 for its rise in Q2 sales. It noted in an earnings release that the latest total accounted for $89 million of accrued customer repayments. Those were associated with refunds from International Emergency Economic Powers Act (IEEPA) tariffs. Those refunds were processed following the U.S. Supreme Court's ruling in February 2026, which found that IEEPA tariffs were not appropriately authorized. Meanwhile, Medline attributed its drop in income to complications related to a June fire. That disaster damaged one of its distribution centers in California. "We delivered robust top-line growth in the quarter, secured over 65% of our annual goal in total new customer signings during the first half of 2026, and moved swiftly to minimize disruption from the fire at our Tracy, California, distribution center, demonstrating an unwavering commitment to our customers," Boyle said. "At the same time, we are effectively managing a dynamic external environment while investing in strategic initiatives to strengthen our market position and support long-term shareholder value creation." Impact from the Tracy fire on Medline. During Medline's Q2 earnings call, Michael Drazin, the company's chief financial officer, assessed that the "Tracy fire impact is transitory and will have some impact rolling in '27." Looking ahead, he told analysts that he expected to see improvements to the situation. Medline is setting up new California distribution centers based in Tracy and Stockton, adding new automation at those facilities. "Obviously, the operational investments and some of the quality investments will be more permanent in nature and will roll into our base in 2027," Drazin said. At the same time, Medline lowered its guidance for adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in its full-year 2026 outlook. That outlook fell to a range of $3.3 billion to $3.4 billion from $3.5 billion to $3.6 billion previously. "Our outlook reflects several headwinds, including the Middle East conflict, the Tracy warehouse fire, growth-related operational investments, quality remediation efforts and softness in our retail business," Boyle stated.
MDLN investigation: Kessler Topaz Meltzer & Check, LLP encourages Medline Inc. (NASDAQ: MDLN) investors to contact the firm. Aug 13, 2026, 18:40 ET RADNOR, Pa., Aug. 13, 2026 /PRNewswire/ - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." Why Did Medline's Stock Drop? Following the news of Medline's FDA violations, the company's stock price fell over 7%. Then, on August 5, 2026, Medline's stock price dropped by over 12% in response to the company's second quarter results and lowered full-year adjusted EBITDA guidance. Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Medline Inc. Class A common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdln-medline-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=mdln&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP
News for rocket scientists. NASDAQ: MDLN investigation reminder: Kessler Topaz Meltzer & Check, LLP encourages Medline Inc. (NASDAQ: MDLN) investors to contact the firm. RADNOR, Pa., Aug. 7, 2026 /PRNewswire/ - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." Why Did Medline's Stock Drop? Following the news of Medline's FDA violations, the company's stock price fell over 7%. Then, on August 5, 2026, Medline's stock price dropped by over 12% in response to the company's second quarter results and lowered full-year adjusted EBITDA guidance. Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Medline Inc. Class A common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdln-medline-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=mdln&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for its clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP
Medline reported second quarter 2026 net sales of $7.7 billion, up 11.6% year-over-year, driven by existing customer growth and new customer implementations. However, net income fell 58.3% to $139 million, primarily due to $336 million in losses from a fire at its Tracy, California distribution centre. The company's adjusted EBITDA rose 13.4% to $1.1 billion in the quarter. For the first six months, net sales increased 11.1% to $15.0 billion, whilst net income dropped 42.3% to $378 million. The results included $243 million in net IEEPA tariff refund benefits following a US Supreme Court ruling. Medline raised its full-year organic sales guidance to 9.0%-10.0% but lowered its adjusted EBITDA outlook to $3.3-$3.4 billion, citing inflationary pressures and operational investments.
Kaplan Fox alerts investors of Medline Inc. (NASDAQ: MDLN) to possible securities law violations. Jul. 21, 2026 1:30 PM ET Source: Kaplan Fox NEW YORK, NY - July 21, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026. According to a June 3, 2026 Reuters article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America - the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act - $800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch. For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this investigation, please contact: Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.